(Q42556865)

English

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

scientific article published on January 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

atrial fibrillation

0 references

author name string

Naccarelli GV

1

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Dorian P

2

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Hohnloser SH

3

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Coumel P

4

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

language of work or name

0 references

publication date

1 January 1996

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

77

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

53A-59A

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Management of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Summary of efficacy and safety of flecainide for supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Comparison of encainide and quinidine for supraventricular tachyarrhythmias.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Flecainide in quinidine-resistant atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2989118-7

7 January 2021

Identifiers

10.1016/S0002-9149(97)89118-7

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42556865&oldid=1961505661"